Loading chat...
NY A10475
Bill
Status
6/3/2022
Primary Sponsor
Yuh-line Niou
Click for details
AI Summary
-
Superintendent of Financial Services must refer insulin to the Drug Accountability Board for examination of all forms of insulin medications under Insurance Law section 202(f)(1)
-
Drug Accountability Board shall examine insulin's impact on commercial insurance premium costs and its affordability and value to New York consumers
-
Board must investigate whether insulin price increases over time were significant and unjustified
-
Board must review the insulin cost-sharing cap established under Part DDD of Chapter 56 of the Laws of 2020 to determine if it is appropriate and suitable for consumer needs
-
Superintendent must publish findings on the Department of Financial Services website and deliver report to the governor, senate president, and assembly speaker within twelve months of the act taking effect
Legislative Description
Requires the Superintendent of Financial Services to refer the drug insulin to the Drug Accountability Board for examination related to price increases and consumer impact.
Last Action
REFERRED TO RULES
6/3/2022